GlassScriptPhysician profile
Brittany Labit-Hernandez
NPI 1255075156
$1,669.07
in general payments reported to CMS, 2019-2025
15 companies · $810 in 2025
The $810 reported for 2025 was more than what 82% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $79.97 · 2023: $537 · 2024: $243 · 2025: $810.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,589.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,589.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $254.46 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $226.26 | 2022-2025 | Lokelma |
| Opko Pharmaceuticals, LLC | $181.07 | 2023-2024 | Rayaldee |
| Akebia Therapeutics INC | $175.48 | 2025 | Vafseo |
| Ardelyx, INC. | $173.58 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Medtronic, INC. | $140.19 | 2025 | Symplicity G3 |
| Calliditas Therapeutics US INC. | $124.61 | 2023 | Tarpeyo |
| Travere Therapeutics, INC. | $101.62 | 2023-2024 | |
| Amgen INC. | $100.75 | 2023-2025 | Tavneos |
| Fresenius USA Marketing, INC. | $95.03 | 2022-2025 | Velphoro, Velphoro |
| Mallinckrodt Hospital Products INC. | $24.55 | 2024 | Terlivaz |
| Vifor Pharma, INC. | $22.97 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.57 | 2025 | |
| Aurinia Pharma U.S., INC. | $16.36 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.57 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Labit-Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.